{"filing":{"accession_number":"0001193125-26-296201","cik":"0001111485","ticker":"RXST","company_name":"RxSight, Inc.","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"rxst-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1111485/000119312526296201/rxst-20260630.htm"},"events":[{"id":17061,"run_id":15274,"accession_number":"0001193125-26-296201","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"summary":"RxSight entered into a material License, Collaboration and Development Agreement with Alcon on June 30, 2026, granting Alcon a non-exclusive, worldwide, royalty-bearing license to develop and commercialize light-adjustable versions of Alcon's simultaneous vision intraocular lenses using RxSight's LAL technology. The agreement provides RxSight with a $60 million upfront payment, up to $140 million in additional milestone payments, and 30% royalties on net sales, constituting a significant strategic collaboration that materially affects RxSight's revenue prospects and market position.","company_name":"RxSight, Inc.","ticker":"RXST","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":15363,"accession_number":"0001193125-26-296201","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"RxSight entered into a material License, Collaboration and Development Agreement with Alcon on June 30, 2026, involving a $60 million upfront payment and up to $140 million in additional milestone payments. The agreement grants Alcon a non-exclusive, worldwide, royalty-bearing license to develop and commercialize light-adjustable versions of Alcon's simultaneous vision intraocular lenses using RxSight's LAL technology, with RxSight receiving 30% royalties on net sales. This constitutes a material strategic collaboration and licensing arrangement that would significantly affect investor assessment of RxSight's revenue prospects and market position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:48:46.430538+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15364,"accession_number":"0001193125-26-296201","item_number":"7.01","item_title":"Regulation FD Information.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"RxSight announced a non-exclusive collaboration agreement with Alcon to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), with RxSight receiving a $60 million upfront payment and up to $140 million in milestone payments. This is a material strategic partnership involving technology development and commercialization rights, but it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control). The event is clearly operational/strategic in nature—a significant business partnership that would affect investor assessment of the company's growth prospects and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:48:46.430538+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15363,"accession_number":"0001193125-26-296201","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"RxSight entered into a material License, Collaboration and Development Agreement with Alcon on June 30, 2026, involving a $60 million upfront payment and up to $140 million in additional milestone payments. The agreement grants Alcon a non-exclusive, worldwide, royalty-bearing license to develop and commercialize light-adjustable versions of Alcon's simultaneous vision intraocular lenses using RxSight's LAL technology, with RxSight receiving 30% royalties on net sales. This constitutes a material strategic collaboration and licensing arrangement that would significantly affect investor assessment of RxSight's revenue prospects and market position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:48:46.430538+00:00","company_name":"RxSight, Inc.","ticker":"RXST","filing_date":"2026-07-06"},{"id":15364,"accession_number":"0001193125-26-296201","item_number":"7.01","item_title":"Regulation FD Information.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"RxSight announced a non-exclusive collaboration agreement with Alcon to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs), with RxSight receiving a $60 million upfront payment and up to $140 million in milestone payments. This is a material strategic partnership involving technology development and commercialization rights, but it does not constitute a traditional M\u0026A transaction (no acquisition, merger, or change of control). The event is clearly operational/strategic in nature—a significant business partnership that would affect investor assessment of the company's growth prospects and revenue potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T12:48:46.430538+00:00","company_name":"RxSight, Inc.","ticker":"RXST","filing_date":"2026-07-06"}]}